Work

The Relative Impact and Future Burden of Prostate Cancer in the United States

Year: 2004

Type: article

Abstract: Efforts to evaluate and discover diagnostic and therapeutic markers for prostate cancer continue. One of these, prostate-specific membrane antigen (PSMA), a transmembrane protein expressed in all types of prostatic tissue, remains a useful diagnostic and possibly therapeutic target. The radio-immunoconjugate form of the anti-PSMA monoclonal antibody 7E11 is used in the commercially available and US Food and Drug Administration-approved diagnostic tool, the ProstaScint(R) (Cytogen Corporation, Princeton, NJ) scan. Recent studies have demonstrated other possible useful roles for PSMA as a target, not only in prostate cancer, but in other malignancies.

Source: The Journal of Urology

DOI: 10.1097/01.ju.0000142068.66876.53

Authors: JUNE M. CHAN, RONALD M. JOU, PETER R. CARROLL

Institution: University of California, San Francisco

Language: English

Topic: Prostate Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: U.S. Public Health Service